High affinity CD16 polymorphism associated with reduced risk of severe COVID-19

By sjmartinez • May 23, 2025

Qualls AE, Tsao T, Lui I, Lim SA, Su Y, Chen E, Duchen D, Maecker HT, Kim-Schulze S, Montgomery RR, Krammer F, Langelier CR, Levy O, Baden LR, Melamed E, Ehrlich LI, McComsey GA, Sekaly RP, Cairns CB, Haddad EK, Shaw AC, Hafler DA, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Agudelo Higuita NI, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeau KC, Davis MM, Fernandez-Sesma A, Simon V, Kraft M, Bime C, Calfee CS, Erle DJ, Schaenmann J, Ozonoff A, Peters B, Kleinstein SH, Augustine AD, Diray-Arce J, Becker PM, Rouphael N, Network I, Goldman JD, Calabrese DR, Heath JR, Wells JA, Reed EF, Lanier LL, Pickering H, Aguilar OA. High affinity CD16 polymorphism associated with reduced risk of severe COVID-19. JCI Insight. 2025 May 22:e191314. doi: 10.1172/jci.insight.191314. Epub ahead of print. PMID: 40402577.

Tags: Cellular immune response, covid-19, Immunology, Infectious Diseases, innate immunity, NK cells, Publications

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab

Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew[...]

Precision medicine evaluation of heterogeneity of treatment effect for a time-to-event outcome with application in a trial of Initial treatment for people living with HIV

Zheng Y, Currier JS, Hughes MD. Precision medicine evaluation of heterogeneity of treatment effect for a time-to-event outcome with application in a trial of Initial[...]

Comparative Effectiveness of Long-Acting Lipoglycopeptides vs Standard-of-Care Antibiotics in Serious Bacterial Infections

Goodman-Meza D, Weiss RE, Poimboeuf ML, Feng J, Vijayan T, Martinello M, Matthews GV, Dore GJ. Comparative Effectiveness of Long-Acting Lipoglycopeptides vs Standard-of-Care Antibiotics in[...]